Comparative Pharmacology
Head-to-head clinical analysis: AGAMREE versus CORTONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AGAMREE versus CORTONE.
AGAMREE vs CORTONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic glucocorticoid receptor agonist; modulates transcription via glucocorticoid response elements, suppressing inflammatory cytokines (e.g., IL-1, IL-6, TNF-α) and immune cell activity.
Cortisone is a corticosteroid that binds to glucocorticoid receptors, leading to decreased inflammation through inhibition of phospholipase A2, reduced cytokine production, and suppression of immune cell migration.
Initial dose: 600 mg (6 tablets of 100 mg or 3 tablets of 200 mg) orally once daily for 4 weeks, then 400 mg orally once daily for weeks 5-8; total treatment duration 8 weeks.
Oral: 25-300 mg daily in 1-4 divided doses; typical initial dose 150-300 mg daily. IM/IV: 100-500 mg every 6-12 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 2.5-3 hours in adults. The half-life may be prolonged in patients with hepatic impairment.
Terminal half-life: 8-12 hours (cortisone) but cortisone is a prodrug; active metabolite cortisol has half-life 1.5-2 hours. Clinical context: duration of action 8-12 hours due to prolonged receptor occupancy.
Primarily hepatic metabolism; <10% excreted unchanged in urine. Fecal excretion accounts for approximately 30% of metabolites. Renal excretion of metabolites accounts for about 60%.
Renal: ~90% as metabolites (glucuronides and sulfates), ~5% unchanged; biliary/fecal: ~5%.
Category C
Category C
Corticosteroid
Corticosteroid